David I Rosenthal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1016971/publications.pdf

Version: 2024-02-01

346 papers 25,403 citations

7551 77 h-index 146 g-index

353 all docs

353 docs citations

times ranked

353

19345 citing authors

#	Article	IF	CITATIONS
1	Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. Clinical and Translational Radiation Oncology, 2022, 32, 35-40.	0.9	3
2	The influence of radiation dose on taste impairment in a prospective observational study cohort of oropharyngeal cancer patients. Acta OncolA ³ gica, 2022, 61, 146-152.	0.8	1
3	Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study. International Journal of Radiation Oncology Biology Physics, 2022, 113, 426-436.	0.4	18
4	Unilateral Radiotherapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papilloma Virus (HPV), Positron-emission Tomography (PET) and Intensity-modulated Radiation Therapy (IMRT). International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	6
5	Enhanced recovery after surgery (ERAS) in head and neck oncologic surgery: Impact on return to intended oncologic therapy (RIOT) and survival. Oral Oncology, 2022, 130, 105906.	0.8	4
6	Cross-Cultural Brain Activity Differences Between True and Sham Acupuncture for Xerostomia During Head and Neck Cancer Radiotherapy. Integrative Cancer Therapies, 2022, 21, 153473542211016.	0.8	0
7	Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Advances in Radiation Oncology, 2022, 7, 100989.	0.6	1
8	Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. British Journal of Cancer, 2021, 124, 628-633.	2.9	17
9	Development and validation of a contouring guideline for the taste bud bearing tongue mucosa. Radiotherapy and Oncology, 2021, 157, 63-69.	0.3	4
10	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer, 2021, 127, 1228-1237.	2.0	2
11	Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer, 2021, 127, 1238-1245.	2.0	6
12	Longitudinal characterization of the tumoral microbiome during radiotherapy in HPV-associated oropharynx cancer. Clinical and Translational Radiation Oncology, 2021, 26, 98-103.	0.9	7
13	Defining the doseâ€volume criteria for laryngeal sparing in locally advanced oropharyngeal cancer utilizing splitâ€field IMRT, wholeâ€field IMRT and VMAT. Journal of Applied Clinical Medical Physics, 2021, 22, 37-44.	0.8	3
14	Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. European Journal of Cancer, 2021, 144, 169-177.	1.3	3
15	Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncology, 2021, 113, 105125.	0.8	12
16	Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head and Neck, 2021, 43, 1592-1603.	0.9	2
17	The impact of induction and/or concurrent chemoradiotherapy on acute and late patientâ€reported symptoms in oropharyngeal cancer: Application of a mixedâ€model analysis of a prospective observational cohort registry. Cancer, 2021, 127, 2453-2464.	2.0	7
18	Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer, 2021, 127, 2916-2925.	2.0	5

#	Article	IF	CITATIONS
19	Vocal-cord Only vs. Complete Laryngeal radiation (VOCAL): a randomized multicentric Bayesian phase II trial. BMC Cancer, 2021, 21, 446.	1.1	7
20	Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores – A pooled analysis of RTOG 0129 and 0522. Oral Oncology, 2021, 116, 105241.	0.8	6
21	Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. International Journal of Particle Therapy, 2021, 8, 261-272.	0.9	4
22	Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. International Journal of Particle Therapy, 2021, 8, 234-247.	0.9	4
23	Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2021, 27, 4557-4565.	3.2	61
24	Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. International Journal of Particle Therapy, 2021, 8, 213-222.	0.9	2
25	Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. Current Treatment Options in Oncology, 2021, 22, 54.	1.3	11
26	Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. International Journal of Particle Therapy, 2021, 8, 108-118.	0.9	8
27	Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy. Radiotherapy and Oncology, 2021, 159, 21-27.	0.3	12
28	Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. International Journal of Particle Therapy, 2021, 8, 319-327.	0.9	11
29	18FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer. Clinical and Translational Radiation Oncology, 2021, 29, 93-101.	0.9	6
30	Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, singleâ€institution, modern cohort study. Head and Neck, 2021, 43, 3331-3344.	0.9	15
31	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 682-695.	0.4	42
32	Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer, 2021, 127, 4413-4420.	2.0	7
33	Factors associated with complex oral treatment device usage in patients with head and neck cancer. Clinical and Translational Radiation Oncology, 2021, 30, 78-83.	0.9	1
34	Therapeutic approaches and outcomes in patients with larynx or hypopharynx highâ€grade neuroendocrine carcinoma: A s ingleâ€center retrospective analysis. Head and Neck, 2021, 43, 3788-3795.	0.9	1
35	Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 2825-2843.	0.8	45
36	Significant Variation in Exercise Recommendations for Youth With Cardiomyopathies or Fontan Circulation. Circulation: Heart Failure, 2021, 14, e008738.	1.6	4

#	Article	IF	Citations
37	An Advanced Communication Skills Workshop Using Standardized Patients for Senior Medical Students. MedEdPORTAL: the Journal of Teaching and Learning Resources, 2021, 17, 11163.	0.5	7
38	Risk stratification after recurrence of human papillomavirus (HPV) â€related and nonâ€HPV â€related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head and Neck, 2021, 44, 158.	0.9	3
39	Tips for Building a Community for Incoming Medical Students Virtually in the COVID-19 Era. Medical Science Educator, 2021, 31, 1-8.	0.7	3
40	Outcomes of carotidâ€sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. Laryngoscope, 2020, 130, 146-153.	1.1	25
41	Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Supportive Care in Cancer, 2020, 28, 261-269.	1.0	12
42	Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 185-193.	0.4	12
43	Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. Journal of Neurological Surgery, Part B: Skull Base, 2020, 81, 638-644.	0.4	7
44	Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiotherapy and Oncology, 2020, 142, 133-139.	0.3	21
45	A prospective evaluation of healthâ€related quality of life after skull base reâ€rradiation. Head and Neck, 2020, 42, 485-497.	0.9	3
46	Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. Cancer, 2020, 126, 749-756.	2.0	8
47	Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 128.	1.2	42
48	Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. Advances in Radiation Oncology, 2020, 5, 929-935.	0.6	8
49	Radiation Oncology Strategies to Flatten the Curve During the Coronavirus Disease 2019 (COVID-19) Pandemic: Experience From a Large Tertiary Cancer Center. Advances in Radiation Oncology, 2020, 5, 567-572.	0.6	12
50	Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. Radiotherapy and Oncology, 2020, 151, 119-125.	0.3	10
51	The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. Clinical and Translational Radiation Oncology, 2020, 24, 71-78.	0.9	11
52	Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. BMC Cancer, 2020, 20, 912.	1.1	31
53	<scp>Highly conformal</scp> reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head and Neck, 2020, 42, 3326-3335.	0.9	14
54	A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue-Deviating Oral Stents. Advances in Radiation Oncology, 2020, 5, 1359-1363.	0.6	7

#	Article	IF	Citations
55	Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases. Physics and Imaging in Radiation Oncology, 2020, 14, 1-5.	1.2	9
56	Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. Radiotherapy and Oncology, 2020, 148, 258-266.	0.3	21
57	Outcomes after radiation therapy for <scp>T2N0</scp> /stage <scp>II</scp> glottic squamous cell carcinoma. Head and Neck, 2020, 42, 2791-2800.	0.9	11
58	Changing practice patterns in head and neck oncologic surgery in the early COVID â€19 era. Head and Neck, 2020, 42, 1179-1186.	0.9	34
59	A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. Oral Oncology, 2020, 106, 104665.	0.8	6
60	Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?. Clinical and Translational Radiation Oncology, 2020, 22, 98-105.	0.9	5
61	Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head and Neck, 2020, 42, 1939-1953.	0.9	29
62	Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors. Scientific Data, 2020, 7, 63.	2.4	6
63	Lymphopenia during radiotherapy in patients with oropharyngeal cancer. Radiotherapy and Oncology, 2020, 145, 95-100.	0.3	18
64	Head and neck surgical oncology in the time of a pandemic: Subsiteâ€specific triage guidelines during the <scp>COVID</scp> ‶9 pandemic. Head and Neck, 2020, 42, 1194-1201.	0.9	38
65	Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiotherapy and Oncology, 2020, 148, 133-139.	0.3	11
66	Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. Head and Neck, 2020, 42, 2137-2144.	0.9	3
67	SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. Practical Radiation Oncology, 2020, 10, 363-371.	1.1	3
68	Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer. Clinical Cancer Research, 2019, 25, 7078-7088.	3.2	21
69	Chronic radiation-associated dysphagia in oropharyngeal cancer survivors: Towards age-adjusted dose constraints for deglutitive muscles. Clinical and Translational Radiation Oncology, 2019, 18, 16-22.	0.9	24
70	Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i>BRAF^{V600E}</i> -Mutated Anaplastic Thyroid Carcinoma. Thyroid, 2019, 29, 1036-1043.	2.4	156
71	Prospective quantitative quality assurance and deformation estimation of MRI-CT image registration in simulation of head and neck radiotherapy patients. Clinical and Translational Radiation Oncology, 2019, 18, 120-127.	0.9	24
72	Six habits of highly successful health information technology: powerful strategies for design and implementation. Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 1109-1114.	2.2	25

#	Article	IF	CITATIONS
73	International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 567-580.	0.4	96
74	Changing functional status within 6 months posttreatment is prognostic of overall survival in patients with head and neck cancer: NRG Oncology Study. Head and Neck, 2019, 41, 3924-3932.	0.9	6
75	Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. Radiation Oncology, 2019, 14, 148.	1.2	30
76	Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. Npj Precision Oncology, 2019, 3, 22.	2.3	31
77	Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. Physics and Imaging in Radiation Oncology, 2019, 10, 29-34.	1.2	2
78	Validation of NRG oncology/RTOGâ€0129 risk groups for HPVâ€positive and HPVâ€negative oropharyngeal squamous cell cancer: Implications for riskâ€based therapeutic intensity trials. Cancer, 2019, 125, 2027-2038.	2.0	58
79	The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. International Journal of Radiation Oncology Biology Physics, 2019, 104, 724-733.	0.4	47
80	Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer, 2019, 125, 1823-1829.	2.0	28
81	Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer. JAMA Network Open, 2019, 2, e1916910.	2.8	49
82	Modeling symptom drivers of oral intake in long-term head and neck cancer survivors. Supportive Care in Cancer, 2019, 27, 1405-1415.	1.0	18
83	A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial. Radiotherapy and Oncology, 2019, 130, 46-55.	0.3	14
84	Intensity modulated proton therapy (IMPT) – The future of IMRT for head and neck cancer. Oral Oncology, 2019, 88, 66-74.	0.8	103
85	Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating. Radiotherapy and Oncology, 2019, 133, 35-42.	0.3	16
86	Radiographic retropharyngeal lymph node involvement in HPVâ€associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. Cancer, 2019, 125, 1536-1546.	2.0	19
87	Singleâ€item discrimination of qualityâ€ofâ€life–altering dysphagia among 714 longâ€term oropharyngeal cancer survivors: Comparison of patientâ€reported outcome measures of swallowing. Cancer, 2019, 125, 1654-1664.	2.0	21
88	Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. Journal of Neurosurgery, 2019, 130, 812-821.	0.9	6
89	OUP accepted manuscript. Journal of the National Cancer Institute Monographs, 2019, 2019, .	0.9	34
90	Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensityâ€modulated radiation therapy. Cancer, 2018, 124, 1415-1427.	2.0	18

#	Article	IF	CITATIONS
91	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncology, 2018, 79, 1-8.	0.8	6
92	Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. Radiotherapy and Oncology, 2018, 126, 75-80.	0.3	19
93	International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiotherapy and Oncology, 2018, 126, 25-36.	0.3	214
94	Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching †liquid biopsy†and quantitative tumor modeling. BMC Cancer, 2018, 18, 903.	1.1	14
95	Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1029-1035.	0.4	18
96	In Regard to Bossi etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 102, 669-670.	0.4	2
97	Symptom Burden Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 1066.	1.2	23
98	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clinical and Translational Radiation Oncology, 2018, 13, 19-23.	0.9	41
99	Ageâ€adjusted comorbidity and survival in locally advanced laryngeal cancer. Head and Neck, 2018, 40, 2060-2069.	0.9	20
100	Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT. Clinical and Translational Radiation Oncology, 2018, 11, 11-18.	0.9	27
101	Radiotherapy dose–volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry. Radiotherapy and Oncology, 2018, 128, 442-451.	0.3	28
102	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. Seminars in Radiation Oncology, 2018, 28, 108-113.	1.0	26
103	A prospective in silico analysis of interdisciplinary and interobserver spatial variability in post-operative target delineation of high-risk oral cavity cancers: Does physician specialty matter?. Clinical and Translational Radiation Oncology, 2018, 12, 40-46.	0.9	16
104	Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Scientific Data, 2018, 5, 180173.	2.4	51
105	Employee Physical Activity in an Outpatient Oncology Clinic: A Baseline Pilot Study. Cureus, 2018, 10, e3803.	0.2	0
106	Long-Term, Prospective Performance of the MDÂAnderson Dysphagia Inventory in "Low-Intermediate Risk―Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 700-708.	0.4	46
107	Superior performance of continuous over pulsatile flow ventricular assist devices in the single ventricle circulation: A computational study. Journal of Biomechanics, 2017, 52, 48-54.	0.9	24
108	Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 532-540.	0.4	54

#	Article	IF	CITATIONS
109	Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head and Neck, 2017, 39, 1609-1620.	0.9	18
110	p16, HPV, and Cetuximab: What Is the Evidence?. Oncologist, 2017, 22, 811-822.	1.9	19
111	Delayed lower cranial neuropathy after oropharyngeal intensityâ€modulated radiotherapy: A cohort analysis and literature review. Head and Neck, 2017, 39, 1516-1523.	0.9	32
112	Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. Laryngoscope, 2017, 127, 842-848.	1.1	37
113	Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer, 2017, 123, 1653-1661.	2.0	55
114	Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head and Neck, 2017, 39, 633-638.	0.9	16
115	Prospective analysis of in vivo landmark point-based MRI geometric distortion in head and neck cancer patients scanned in immobilized radiation treatment position: Results of a prospective quality assurance protocol. Clinical and Translational Radiation Oncology, 2017, 7, 13-19.	0.9	13
116	Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. Radiotherapy and Oncology, 2017, 124, 232-239.	0.3	69
117	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncology, The, 2017, 18, 1221-1237.	5.1	226
118	Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. Head and Neck, 2017, 39, 2079-2087.	0.9	15
119	Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions. Radiotherapy and Oncology, 2017, 124, 248-255.	0.3	32
120	Cognitive function and patientâ€reported memory problems after radiotherapy for cancers at the skull base: A crossâ€sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventoryâ€Head and Neck Module. Head and Neck, 2017, 39, 2048-2056.	0.9	5
121	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. Clinical and Translational Radiation Oncology, 2017, 7, 28-35.	0.9	18
122	Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and NeckÂCancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1002-1011.	0.4	86
123	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. International Journal of Radiation Oncology Biology Physics. 2017. 97. 687-699.	0.4	35
124	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. International Journal of Radiation Oncology Biology Physics, 2017, 97, 667-677.	0.4	30
125	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65Âyears old. Radiation Oncology, 2017, 12, 150.	1.2	25
126	Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. Radiation Oncology, 2017, 12, 129.	1.2	8

#	Article	IF	Citations
127	Design and fabrication of a 3D–printed oral stent for head and neck radiotherapy from routine diagnostic imaging. 3D Printing in Medicine, 2017, 3, 12.	1.7	31
128	Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Journal of Clinical Oncology, 2017, 35, 4078-4090.	0.8	45
129	Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. Journal of Clinical Oncology, 2017, 35, 4057-4065.	0.8	124
130	Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncology, 2017, 72, 90-97.	0.8	28
131	Methodology for analysis and reporting patterns of failure in the Era of IMRT: head and neck cancer applications. Radiation Oncology, 2016, 11, 95.	1.2	34
132	Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus–associated oropharyngeal cancer. Cancer, 2016, 122, 1702-1707.	2.0	17
133	Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. Head and Neck, 2016, 38, E452-8.	0.9	32
134	Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensityâ€modulated radiotherapy. Head and Neck, 2016, 38, E925-33.	0.9	22
135	Prognostic value of p16 expression in Epsteinâ€Barr virus–positive nasopharyngeal carcinomas. Head and Neck, 2016, 38, E1459-66.	0.9	28
136	Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus–associated oropharyngeal cancer. Head and Neck, 2016, 38, E1554-61.	0.9	11
137	Outcomes for hypopharyngeal carcinoma treated with organâ€preservation therapy. Head and Neck, 2016, 38, E2091-9.	0.9	14
138	Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. International Journal of Cancer, 2016, 138, 1290-1297.	2.3	17
139	Improved setup and positioning accuracy using a threeâ€point customized cushion/mask/biteâ€block immobilization system for stereotactic reirradiation of head and neck cancer. Journal of Applied Clinical Medical Physics, 2016, 17, 180-189.	0.8	32
140	CT-based volumetric tumor growth velocity: A novel imaging prognostic indicator in oropharyngeal cancer patients receiving radiotherapy. Oral Oncology, 2016, 63, 16-22.	0.8	7
141	A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. International Journal of Radiation Oncology Biology Physics, 2016, 95, 344-352.	0.4	49
142	Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129. International Journal of Radiation Oncology Biology Physics, 2016, 96, 362-371.	0.4	22
143	Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal dose–response characterization of quantitative signal kinetics. Radiotherapy and Oncology, 2016, 118, 315-322.	0.3	21
144	The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Practical Radiation Oncology, 2016, 6, 241-247.	1.1	41

#	Article	IF	Citations
145	Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose–volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. Radiotherapy and Oncology, 2016, 118, 304-314.	0.3	85
146	Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. International Journal of Radiation Oncology Biology Physics, 2016, 96, 30-41.	0.4	123
147	Quantitative body mass characterization before and after head and neck cancer radiotherapy: A challenge of height-weight formulae using computed tomography measurement. Oral Oncology, 2016, 61, 62-69.	0.8	29
148	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis. Radiotherapy and Oncology, 2016, 120, 48-55.	0.3	177
149	Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. Radiotherapy and Oncology, 2016, 121, 381-386.	0.3	78
150	Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial. European Journal of Cancer, 2016, 64, 1-11.	1.3	26
151	Longâ€term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. Head and Neck, 2016, 38, 1739-1751.	0.9	33
152	Reply to radiotherapy for human papillomavirusâ€positive oropharyngeal cancers in the National Cancer Data Base. Cancer, 2016, 122, 3411-3412.	2.0	1
153	Meaning and the Nature of Physicians' Work. New England Journal of Medicine, 2016, 375, 1813-1815.	13.9	44
154	Intensityâ€modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes. Head and Neck, 2016, 38, E1886-95.	0.9	102
155	Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. Medical Dosimetry, 2016, 41, 189-194.	0.4	62
156	Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: TheÂRTOG Experience. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1346-1354.	0.4	28
157	Orbital carcinomas treated with adjuvant intensityâ€modulated radiation therapy. Head and Neck, 2016, 38, E580-7.	0.9	10
158	Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. Head and Neck, 2016, 38, E1472-80.	0.9	36
159	Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1117-1131.	0.4	100
160	Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. JAMA Oncology, 2016, 2, 782.	3.4	185
161	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1107-1114.	0.4	121
162	Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 95, 360-367.	0.4	88

#	Article	IF	Citations
163	Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. Journal of Clinical Oncology, 2016, 34, 1300-1308.	0.8	190
164	Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma. International Journal of Particle Therapy, 2016, 2, 533-543.	0.9	16
165	Linguistic Validation of the Turkish Version of the M.D. Anderson Symptom Inventory - Head and Neck Cancer Module. Balkan Medical Journal, 2016, 33, 339-343.	0.3	2
166	Normal Tissue Complications and Protection in Head and Neck Cancer Patients., 2016,, 753-767.		0
167	Multidisciplinary Management of Oropharynx Carcinomas. , 2016, , 475-510.		0
168	Estimation of daily interfractional larynx residual setup error after isocentric alignment for head and neck radiotherapy: quality assurance implications for target volume and organsâ€atâ€risk margination using daily CT onâ€rails imaging. Journal of Applied Clinical Medical Physics, 2015, 16, 159-169.	0.8	13
169	Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. NMR in Biomedicine, 2015, 28, 1645-1654.	1.6	51
170	Auto-segmentation of the brachial plexus assessed with TaCTICS – A software platform for rapid multiple-metric quantitative evaluation of contours. Acta Oncológica, 2015, 54, 562-566.	0.8	4
171	Prospective observer and software-based assessment of magnetic resonance imaging quality in head and neck cancer: Should standard positioning and immobilization be required for radiation therapy applications?. Practical Radiation Oncology, 2015, 5, e299-e308.	1.1	31
172	Lymphedema Outcomes in Patients with Head and Neck Cancer. Otolaryngology - Head and Neck Surgery, 2015, 152, 284-291.	1.1	91
173	The symptom burden of treatmentâ€naive patients with head and neck cancer. Cancer, 2015, 121, 766-773.	2.0	56
174	Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: Quantitative image analysis of post-radiotherapy response. Oral Oncology, 2015, 51, 195-201.	0.8	13
175	Institutional Clinical Trial Accrual Volume and Survival of Patients With Head and Neck Cancer. Journal of Clinical Oncology, 2015, 33, 156-164.	0.8	216
176	Improved human observer performance in digital reconstructed radiograph verification in head and neck cancer radiotherapy. International Journal of Computer Assisted Radiology and Surgery, 2015, 10, 1667-1673.	1.7	4
177	Quality Assurance Assessment of Diagnostic and Radiation Therapy–Simulation CT Image Registration for Head and Neck Radiation Therapy: Anatomic Region of Interest–based Comparison of Rigid and Deformable Algorithms. Radiology, 2015, 274, 752-763.	3.6	58
178	Final Report of Radiation Therapy Oncology Group Protocol 9003: Provocative, but Limited Conclusions From Exploratory Analyses. International Journal of Radiation Oncology Biology Physics, 2015, 92, 715-717.	0.4	3
179	Reply to B. O'Sullivan et al. Journal of Clinical Oncology, 2015, 33, 1708-1709.	0.8	11
180	A multiâ€institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensityâ€modulated radiotherapy. Cancer, 2015, 121, 294-301.	2.0	109

#	Article	IF	CITATIONS
181	Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head-and-Neck Cancer: Pilot Results From Radiation Therapy Oncology Group Protocol 0522. International Journal of Radiation Oncology Biology Physics, 2015, 91, 721-729.	0.4	64
182	Analysis of Charges Associated with Definitive Nonsurgical Therapy for Early-Stage Lateralized Tonsil Cancer. Annals of Surgical Oncology, 2015, 22, 2755-2760.	0.7	0
183	Longâ€term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3â€decade survey. Cancer, 2015, 121, 1608-1619.	2.0	100
184	Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. Radiotherapy and Oncology, 2015, 117, 132-138.	0.3	21
185	Comparison of measurement methods with a mixed effects procedure accounting for replicated evaluations (COM3PARE): method comparison algorithm implementation for head and neck IGRT positional verification. BMC Medical Imaging, 2015, 15, 35.	1.4	2
186	CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiotherapy and Oncology, 2015, 117, 83-90.	0.3	425
187	Proton Therapy Reduces Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Match Control Study of Intensity-Modulated Proton Therapy and Intensity-Modulated Photon Therapy. International Journal of Particle Therapy, 2015, 2, 19-28.	0.9	76
188	Prospective randomized double-blind study of atlas-based organ-at-risk autosegmentation-assisted radiation planning in head and neck cancer. Radiotherapy and Oncology, 2014, 112, 321-325.	0.3	96
189	Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventoryâ€Head and Neck Module. Cancer, 2014, 120, 1975-1984.	2.0	106
190	Randomized Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Long-Term Report of Efficacy and Toxicity. Journal of Clinical Oncology, 2014, 32, 3858-3867.	0.8	363
191	Clinical characteristics of patients with multiple potentially human papillomavirus-related malignancies. Head and Neck, 2014, 36, 819-825.	0.9	5
192	Risk factors for clinicianâ€reported symptom clusters in patients with advanced head and neck cancer in a phase 3 randomized clinical trial: RTOG 0129. Cancer, 2014, 120, 848-854.	2.0	28
193	Nomogram for Predicting Symptom Severity during Radiation Therapy for Head and Neck Cancer. Otolaryngology - Head and Neck Surgery, 2014, 151, 619-626.	1.1	18
194	Beam path toxicity in candidate organs-at-risk: Assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. Radiotherapy and Oncology, 2014, 111, 281-288.	0.3	54
195	Auto-segmentation of low-risk clinical target volume for head and neck radiation therapy. Practical Radiation Oncology, 2014, 4, e31-e37.	1.1	28
196	Development of a Software for Quantitative Evaluation Radiotherapy Target and Organ-at-Risk Segmentation Comparison. Journal of Digital Imaging, 2014, 27, 108-119.	1.6	10
197	Optimization of longâ€term outcomes for patients with esthesioneuroblastoma. Head and Neck, 2014, 36, 524-530.	0.9	88
198	Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 3365-3373.	0.8	449

#	Article	IF	CITATIONS
199	Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522. Journal of Clinical Oncology, 2014, 32, 2940-2950.	0.8	697
200	Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncology, 2014, 50, 765-769.	0.8	20
201	Management of the lymph nodeâ€positive neck in the patient with human papillomavirusâ€associated oropharyngeal cancer. Cancer, 2014, 120, 3082-3088.	2.0	27
202	Multifield Optimization Intensity Modulated Proton Therapy for Head and Neck Tumors: A Translation to Practice. International Journal of Radiation Oncology Biology Physics, 2014, 89, 846-853.	0.4	128
203	Late radiation-associated dysphagia (late-RAD) with lower cranial neuropathy after oropharyngeal radiotherapy: A preliminary dosimetric comparison. Oral Oncology, 2014, 50, 746-752.	0.8	56
204	Residual nodal disease in patients with advancedâ€stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. Head and Neck, 2013, 35, 1454-1460.	0.9	12
205	High symptom burden prior to radiation therapy for head and neck cancer: A patientâ€reported outcomes study. Head and Neck, 2013, 35, 1490-1498.	0.9	48
206	Early postoperative epidermal growth factor receptor inhibition: Safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo. Head and Neck, 2013, 35, 321-328.	0.9	14
207	Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiation Oncology, 2013, 8, 21.	1.2	89
208	Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Quality of Life Research, 2013, 22, 2331-2339.	1.5	38
209	Patterns of Disease Recurrence Following Treatment of Oropharyngeal Cancer With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 941-947.	0.4	99
210	Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies: A treatment planning comparison. Medical Dosimetry, 2013, 38, 390-394.	0.4	88
211	An exploratory study of the informational and psychosocial needs of patients with human papillomavirus-associated oropharyngeal cancer. Oral Oncology, 2013, 49, 1067-1071.	0.8	41
212	Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy. Oral Oncology, 2013, 49, 360-366.	0.8	76
213	Instant replay. Healthcare, 2013, 1, 52-54.	0.6	4
214	Adaptive radiotherapy for head and neck cancerâ€"Dosimetric results from a prospective clinical trial. Radiotherapy and Oncology, 2013, 106, 80-84.	0.3	168
215	Prospective assessment of an atlas-based intervention combined with real-time software feedback in contouring lymph node levels and organs-at-risk in the head and neck: Quantitative assessment of conformance to expert delineation. Practical Radiation Oncology, 2013, 3, 186-193.	1.1	20
216	The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. Cancer, 2013, 119, 3162-3169.	2.0	49

#	Article	IF	Citations
217	A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2012, 18, 1435-1446.	3.2	164
218	Prediction of Neck Dissection Requirement After Definitive Radiotherapy for Head-and-Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, e367-e374.	0.4	62
219	Unilateral Radiotherapy for the Treatment of Tonsil Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 204-209.	0.4	94
220	Sham-controlled, randomised, feasibility trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. European Journal of Cancer, 2012, 48, 1692-1699.	1.3	55
221	Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. Head and Neck, 2012, 34, 1263-1268.	0.9	48
222	Randomized controlled trial of acupuncture for prevention of radiationâ€induced xerostomia among patients with nasopharyngeal carcinoma. Cancer, 2012, 118, 3337-3344.	2.0	84
223	Linguistic validation of the Greek M.D. Anderson Symptom Inventory - Head and Neck Module. , 2012, 3, 29-31.		2
224	Sinonasal neuroendocrine carcinoma: impact of differentiation status on response and outcome. Head & Neck Oncology, 2011, 3, 32.	2.3	49
225	Outcomes of malignant tumors of the lacrimal apparatus. Cancer, 2011, 117, 2801-2810.	2.0	62
226	Effect of Brain Stem and Dorsal Vagus Complex Dosimetry on Nausea and Vomiting in Head and Neck Intensity-Modulated Radiation Therapy. Medical Dosimetry, 2011, 36, 41-45.	0.4	24
227	Induction Chemotherapy for Advanced Squamous Cell Carcinoma of the Paranasal Sinuses. JAMA Otolaryngology, 2011, 137, 78.	1.5	113
228	Normal Tissue Complications and Protection in Head and Neck Cancer Patients. , 2011, , 613-628.		0
229	Multidisciplinary Management of Oropharynx Carcinomas. , 2011, , 401-430.		0
230	Outcomes of patients with tonsillar carcinoma treated with postâ€ŧonsillectomy radiation therapy. Head and Neck, 2010, 32, 473-480.	0.9	15
231	Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head and Neck, 2010, 32, 829-836.	0.9	80
232	Compliance with quality assurance measures in patients treated for early oral tongue cancer. Cancer, 2010, 116, 3408-3416.	2.0	39
233	Simple Carotid-Sparing Intensity-Modulated Radiotherapy Technique and Preliminary Experience for T1–2 Glottic Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 455-461.	0.4	89
234	Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 667-674.	0.4	21

#	Article	IF	CITATIONS
235	Intensity-Modulated Radiotherapy for Cervical Node Squamous Cell Carcinoma Metastases From Unknown Head-and-Neck Primary Site: M. D. Anderson Cancer Center Outcomes and Patterns of Failure. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1005-1010.	0.4	75
236	Candidate Dosimetric Predictors of Long-Term Swallowing Dysfunction After Oropharyngeal Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1356-1365.	0.4	156
237	Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. New England Journal of Medicine, 2010, 363, 24-35.	13.9	5,481
238	Early Postoperative Paclitaxel Followed by Concurrent Paclitaxel and Cisplatin With Radiation Therapy for Patients With Resected High-Risk Head and Neck Squamous Cell Carcinoma: Report of the Phase II Trial RTOG 0024. Journal of Clinical Oncology, 2009, 27, 4727-4732.	0.8	40
239	Method comparison of automated matching software-assisted cone-beam CT and stereoscopic kilovoltage x-ray positional verification image-guided radiation therapy for head and neck cancer: a prospective analysis. Physics in Medicine and Biology, 2009, 54, 7401-7415.	1.6	9
240	Strategies for Managing Radiation-Induced Mucositis in Head and Neck Cancer. Seminars in Radiation Oncology, 2009, 19, 29-34.	1.0	153
241	Hypothyroidism in older patients with head and neck cancer after treatment with radiation: A populationâ€based study. Head and Neck, 2009, 31, 1031-1038.	0.9	30
242	Acupuncture for radiationâ€induced xerostomia in patients with cancer: A pilot study. Head and Neck, 2009, 31, 1360-1368.	0.9	52
243	The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer, 2009, 115, 5723-5733.	2.0	210
244	IMRT Reirradiation of Head and Neck Cancer—Disease Control and Morbidity Outcomes. International Journal of Radiation Oncology Biology Physics, 2009, 73, 399-409.	0.4	218
245	Postoperative External Beam Radiotherapy for Differentiated Thyroid Cancer: Outcomes and Morbidity With Conformal Treatment. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1083-1091.	0.4	143
246	Molecular and phenotypic analysis of poorly differentiated sinonasal neoplasms: an integrated approach for early diagnosis and classification. Human Pathology, 2009, 40, 283-292.	1.1	49
247	Prospective Risk-Adjusted [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. Journal of Clinical Oncology, 2009, 27, 2509-2515.	0.8	156
248	Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer, 2008, 112, 111-118.	2.0	56
249	Epithelial to mesenchymal transition in head and neck squamous carcinoma. Cancer, 2008, 112, 2088-2100.	2.0	184
250	Postoperative radiotherapy for advanced medullary thyroid cancer—Local disease control in the modern era. Head and Neck, 2008, 30, 883-888.	0.9	78
251	Comparison of 2D Radiographic Images and 3D Cone Beam Computed Tomography for Positioning Head-and-Neck Radiotherapy Patients. International Journal of Radiation Oncology Biology Physics, 2008, 71, 916-925.	0.4	112
252	Beam Path Toxicities to Non-Target Structures During Intensity-Modulated Radiation Therapy for Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 747-755.	0.4	168

#	Article	IF	Citations
253	The M. D. Anderson Symptom Inventory–Head and Neck Module, a Patient-Reported Outcome Instrument, Accurately Predicts the Severity of Radiation-Induced Mucositis. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1355-1361.	0.4	72
254	Phase I Study of Preoperative Radiation Therapy With Concurrent Infusional 5-Fluorouracil and Oxaliplatin Followed by Surgery and Postoperative 5-Fluorouracil Plus Leucovorin for T3/T4 Rectal Adenocarcinoma: ECOG E1297. International Journal of Radiation Oncology Biology Physics, 2008, 72, 108-113.	0.4	24
255	Swallowing Outcomes After Radiotherapy for Laryngeal Carcinoma. JAMA Otolaryngology, 2008, 134, 178.	1.5	74
256	Cerebrovascular Disease Risk in Older Head and Neck Cancer Patients After Radiotherapy. Journal of Clinical Oncology, 2008, 26, 5119-5125.	0.8	206
257	Phase II Study of Palifermin and Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2008, 26, 2489-2496.	0.8	94
258	Sinonasal Teratocarcinosarcoma of the Head and Neck. JAMA Otolaryngology, 2008, 134, 592.	1.5	64
259	Postoperative Adjuvant External-Beam Radiation Therapy for Cancers of the Eyelid and Conjunctiva. Ophthalmic Plastic and Reconstructive Surgery, 2008, 24, 444-449.	0.4	45
260	Phase II Trial of Chemoradiation for Organ Preservation in Resectable Stage III or IV Squamous Cell Carcinomas of the Larynx or Oropharynx: Results of Eastern Cooperative Oncology Group Study E2399. Journal of Clinical Oncology, 2007, 25, 3971-3977.	0.8	136
261	Effect of Initial Treatment on Disease Outcome for Patients With Submandibular Gland Carcinoma. JAMA Otolaryngology, 2007, 133, 546.	1.5	36
262	Differential Expression of Hormonal and Growth Factor Receptors in Salivary Duct Carcinomas. American Journal of Surgical Pathology, 2007, 31, 1645-1652.	2.1	179
263	The Effect of Dental Artifacts, Contrast Media, and Experience on Interobserver Contouring Variations in Head and Neck Anatomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 191-198.	0.6	33
264	Radiation-induced xerostomia. Head and Neck, 2007, 29, 58-63.	0.9	65
265	Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module. Head and Neck, 2007, 29, 923-931.	0.9	227
266	Conditional survival in head and neck squamous cell carcinoma. Cancer, 2007, 109, 1331-1343.	2.0	134
267	Sinonasal adenoid cystic carcinoma. Cancer, 2007, 110, 2726-2731.	2.0	148
268	A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 445-452.	0.4	63
269	Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 67, 438-444.	0.4	130
270	Postoperative Radiotherapy for Maxillary Sinus Cancer: Long-Term Outcomes and Toxicities of Treatment. International Journal of Radiation Oncology Biology Physics, 2007, 68, 719-730.	0.4	86

#	Article	IF	Citations
271	Increasing Toxicity in Nonoperative Head and Neck Cancer Treatment: Investigations and Interventions. International Journal of Radiation Oncology Biology Physics, 2007, 69, S79-S82.	0.4	26
272	Parotid Gland Dose in Intensity-Modulated Radiotherapy for Head and Neck Cancer: Is What You Plan What You Get?. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1290-1296.	0.4	130
273	Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes. The Journal of Supportive Oncology, 2007, 5, 23-31.	2.3	67
274	Prevention and Treatment of Dysphagia and Aspiration After Chemoradiation for Head and Neck Cancer. Journal of Clinical Oncology, 2006, 24, 2636-2643.	0.8	358
275	Merkel cell carcinoma of the tongue and head and neck oral mucosal sites. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2006, 101, 761-768.	1.6	45
276	Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent with Radiation Therapy for Locally Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 38-45.	0.5	0
277	Preliminary Investigation of Symptom Distress in the Head and Neck Patient Population. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 158-162.	0.6	26
278	Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. International Journal of Radiation Oncology Biology Physics, 2006, 64, 678-683.	0.4	83
279	Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1559-1569.	0.4	165
280	Two-field versus three-field irradiation technique in the postoperative treatment of head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 469-476.	0.4	4
281	Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. European Archives of Oto-Rhino-Laryngology, 2006, 263, 313-318.	0.8	25
282	Impact of changes to the American Joint Committee on Cancer T classification on outcome prediction in patients with oropharyngeal cancer. Cancer, 2006, 106, 1950-1957.	2.0	5
283	Importance of patient examination to clinical quality assurance in head and neck radiation oncology. Head and Neck, 2006, 28, 967-973.	0.9	70
284	Established and Emerging Uses of Cytoprotection in Head and Neck Cancer. JAMA Otolaryngology, 2006, 132, 129.	1.5	2
285	Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent with Radiation Therapy for Locally Advanced Non???Small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 38-45.	0.5	4
286	Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer. Journal of Thoracic Oncology, 2006, 1, 38-45.	0.5	0
287	Survival Impact of Planned Restaging and Early Surgical Salvage Following Definitive Chemoradiation for Locally Advanced Squamous Cell Carcinomas of the Oropharynx and Hypopharynx. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 385-392.	0.6	54
288	Genetic analysis of sinonasal adenocarcinoma phenotypes: distinct alterations of histogenetic significance. Modern Pathology, 2005, 18, 315-319.	2.9	64

#	Article	IF	Citations
289	Postoperative treatment intensification for improving outcome in the high-risk patient: An evolutionary process. Head and Neck, 2005, 27, 841-842.	0.9	0
290	Intensity-modulated radiotherapy: Is xerostomia still prevalent?. Current Oncology Reports, 2005, 7, 131-136.	1.8	33
291	Head and neck squamous cell carcinoma: optimizing the therapeutic index. Expert Review of Anticancer Therapy, 2005, 5, 501-514.	1.1	14
292	Does concurrent postoperative radiotherapy and chemotherapy in head and neck cancer improve patient outcome?. Nature Clinical Practice Oncology, 2004, 1, 14-15.	4.3	2
293	Differential Methylation Status of Tumor-Associated Genes in Head and Neck Squamous Carcinoma. Clinical Cancer Research, 2004, 10, 3825-3830.	3.2	140
294	A multinational, randomized phase iii trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology Biology Physics, 2004, 58, 674-681.	0.4	119
295	A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Seminars in Oncology, 2004, 31, 25-28.	0.8	44
296	Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Seminars in Radiation Oncology, 2004, 14, 103-109.	1.0	62
297	Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma. Seminars in Radiation Oncology, 2004, 14, 153-166.	1.0	35
298	Parathyroid carcinoma: A 22-year experience. Head and Neck, 2004, 26, 716-726.	0.9	233
299	Controversies in the management of advanced laryngeal squamous cell carcinoma. Cancer, 2004, 101, 211-219.	2.0	15
300	Sinonasal malignancies with neuroendocrine differentiation. Cancer, 2004, 101, 2567-2573.	2.0	187
301	Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 72-77.	0.4	63
302	Radiation therapy for early-stage carcinoma of the oropharynx. International Journal of Radiation Oncology Biology Physics, 2004, 59, 743-751.	0.4	62
303	Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. International Journal of Radiation Oncology Biology Physics, 2004, 59, 960-970.	0.4	643
304	New equations for matching a low neck field to oblique upper neck fields with collimator rotation in a 3-field monoisocentric setup for head-and-neck cancers. Medical Dosimetry, 2004, 29, 86-91.	0.4	0
305	Final Report of a Pilot Trial of Accelerated Radiotherapy Plus Concurrent 96-Hour Infusional Paclitaxel for Locally Advanced Head and Neck Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 595-602.	0.6	10
306	Molecular and Clinicopathologic Comparisons of Head and Neck Squamous Carcinoma Variants. American Journal of Surgical Pathology, 2004, 28, 1299-1310.	2.1	46

#	Article	IF	Citations
307	The prevention and treatment of radiotherapy-induced xerostomia. Seminars in Radiation Oncology, 2003, 13, 302-308.	1.0	24
308	How should we measure and report radiotherapy-induced xerostomia?. Seminars in Radiation Oncology, 2003, 13, 226-234.	1.0	135
309	Management of nonsinonasal neuroendocrine carcinomas of the head and neck. Cancer, 2003, 98, 2322-2328.	2.0	77
310	Modification of Gill-Thomas-Cosman frame for extracranial head-and-neck stereotactic radiotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1192-1195.	0.4	6
311	Comparison of stages l–II thymoma treated by complete resection with or without adjuvant radiation. Annals of Thoracic Surgery, 2003, 76, 1635-1642.	0.7	169
312	Sarcomatoid Carcinoma of the Head and Neck. American Journal of Surgical Pathology, 2003, 27, 1216-1220.	2.1	106
313	Parotidectomy in the Treatment of Aggressive Cutaneous Malignancies. JAMA Otolaryngology, 2002, 128, 521.	1.5	45
314	Nasopharyngeal Carcinoma Treated With External Radiotherapy, Brachytherapy, and Concurrent/Adjuvant Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 93-95.	0.6	22
315	Organ Preservation Therapy Using Induction Plus Concurrent Chemoradiation for Advanced Resectable Oropharyngeal Carcinoma: A University of Pennsylvania Phase II Trial. Journal of Clinical Oncology, 2002, 20, 3964-3971.	0.8	210
316	Prediction of Treatment Response of Head and Neck Cancers with P-31 MR Spectroscopy from Pretreatment Relative Phosphomonoester Levels. Academic Radiology, 2002, 9, 688-694.	1.3	38
317	Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head and Neck, 2002, 24, 115-126.	0.9	189
318	Desmoplastic neurotropic melanoma of the head and neck: The role of radiation therapy. Head and Neck, 2002, 24, 1068-1071.	0.9	32
319	Relative Risk of Stroke in Head and Neck Carcinoma Patients Treated With External Cervical Irradiation. Laryngoscope, 2002, 112, 1883-1887.	1.1	96
320	A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Investigational New Drugs, 2002, 20, 343-349.	1.2	40
321	Reinterpretation of cross-sectional images in patients with head and neck cancer in the setting of a multidisciplinary cancer center. American Journal of Neuroradiology, 2002, 23, 1622-6.	1.2	69
322	Advanced oropharyngeal carcinoma treated with surgery and radiotherapy: Oncologic outcome and functional assessment. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2001, 22, 329-335.	0.6	55
323	Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent With Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2001, 19, 1363-1373.	0.8	34
324	A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors. Medical and Pediatric Oncology, 2001, 37, 390-392.	1.0	15

#	Article	IF	CITATIONS
325	Pilot Study of Organ Preservation Multimodality Therapy for Locally Advanced Resectable Oropharyngeal Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 509-515.	0.6	13
326	Reversible Renal Toxicity Resulting From High Single Doses of the New Radiosensitizer Gadolinium Texaphyrin. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 593-598.	0.6	17
327	Allograft Dermal Implant (AlloDerm) in a Previously Irradiated Field. Laryngoscope, 2000, 110, 934-937.	1.1	54
328	Effects of external beam radiation on the allograft dermal implant. Otolaryngology - Head and Neck Surgery, 2000, 122, 189-194.	1.1	39
329	Hypopharyngeal Desmoid Tumor. Otolaryngology - Head and Neck Surgery, 2000, 123, 279-281.	1.1	6
330	Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18f-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope, 1999, 109, 970-975.	1.1	105
331	Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1345.	2.2	261
332	Photodynamic Therapy in the Treatment of Cancer. Drugs, 1999, 57, 725-734.	4.9	153
333	Dosimetric comparison of centered and off-centered posterior neck electron fields. Medical Dosimetry, 1998, 23, 284-287.	0.4	0
334	The effect of independent collimator misalignment on the dosimetry of abutted half-beam blocked fields for the treatment of head and neck cancer. Radiotherapy and Oncology, 1998, 49, 273-278.	0.3	40
335	Prophylactic Gastrostomy Tubes in Patients Undergoing Intensive Irradiation for Cancer of the Head and Neck. JAMA Otolaryngology, 1998, 124, 871.	1.5	218
336	Osteoinduction Using Bone Morphogenic Protein in Irradiated Tissue. JAMA Otolaryngology, 1998, 124, 985.	1.5	40
337	We've Got a Treatment, but What's the Disease?. Oncologist, 1996, 1, 1-7.	1.9	18
338	Head and Neck Radiation Therapy: Basic and Advanced Techniques. Otolaryngology - Head and Neck Surgery, 1995, 112, P115-P115.	1.1	0
339	RE: SF2: Clothes for the emperor?. Radiotherapy and Oncology, 1995, 34, 81.	0.3	3
340	Clinical Applications of Photodynamic Therapy. Annals of Medicine, 1994, 26, 405-409.	1.5	23
341	A review of neoadjuvant chemotherapy for head and neck cancer: Partially shrunken tumors may be both leaner and meaner. International Journal of Radiation Oncology Biology Physics, 1994, 28, 315-320.	0.4	55
342	Metronidazole in Head and Neck Surgeryâ€"The Effect of Lengthened Prophylaxis. Otolaryngology - Head and Neck Surgery, 1990, 103, 1009-1011.	1.1	15

#	Article	IF	CITATION
343	Direct Nerve Implantation Vs. Nerve-Muscle Pedicle: A Comparative Study of Reinnervation in the Rabbit. Otolaryngology - Head and Neck Surgery, 1989, 100, 126-133.	1.1	7
344	Dynamic Rehabilitation of the Paralyzed Face: I. Electronic Control of Reinnervated Muscles from Intact Facial Musculature in the Rabbit. Otolaryngology - Head and Neck Surgery, 1987, 97, 441-445.	1.1	17
345	Group Therapy of Alcoholics with Concurrent Group Meetings of their Wives. Quarterly Journal of Studies on Alcohol, 1956, 17, 655-670.	0.3	36
346	The effects of mephenesin and practice on the Bender-Gestalt performance of psychiatric outpatients. Journal of Clinical Psychology, 1955, 11, 90-92.	1.0	5